Physician profile
John Anthon Laratta
NPI 1336125574
$2,773.55
in general payments reported to CMS, 2019-2025
22 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,817 · 2020: $486 · 2021: $248 · 2023: $80.65 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $222.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,263.31 | 2019-2025 | Everest Spinal System |
| Sanofi-Aventis U.S. LLC | $300.00 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $253.05 | 2019-2021 | |
| Amgen INC. | $168.21 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $106.06 | 2019 | |
| Zimmer Biomet Holdings, INC. | $104.03 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $80.65 | 2023 | Camzyos |
| Ethicon US, LLC | $79.08 | 2019 | |
| Amarin Pharma, INC. | $76.89 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $54.64 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.43 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $54.10 | 2020 | |
| Novo Nordisk INC | $29.56 | 2021 | |
| Novartis Pharmaceuticals Corporation | $27.00 | 2019-2020 | |
| Glaxosmithkline, LLC. | $25.59 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $15.31 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.02 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.50 | 2020 | |
| Corcept Therapeutics | $13.61 | 2021 | |
| Allergan, INC. | $13.32 | 2020 | |
| Lilly USA, LLC | $12.67 | 2021 | |
| Qiagen, LLC | $12.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Laratta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.